Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Annexin A13 Protects Against Acute Kidney Injury by Inactivating TGF-β/Smad3 Signaling.
PMID 41486854 · PMC12915081 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · 8 claims · 8 setups
ANXA13 is selectively downregulated in the kidneys of AKI patients and IRI- or cisplatin-induced AKI mice, primarily in proximal tubular cells
-
Has reproduction · 100
Differential Gene Expression and Methylation Analysis of Melanoma in TCGA Database to Further Study the Expression Pattern of KYNU in Melanoma.
PMID 35893303 · PMC9329910 · Journal of personalized medicine · 2022 · 8 claims · 8 setups
Oncogenes MITF, KIT, CDH1, NRAS, AKT1, EGFR, TP53, and CDK4 are elevated while tumor suppressors PTEN, cAMP, and BCL2 are reduced in melanoma
-
Has reproduction · 69
Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.
PMID 39183332 · PMC11345443 · Cell death & disease · 2024 · 7 claims · 8 setups
Pax5 is an important transcription factor driving neuronal gene expression and is specific to t-NEPC
-
Full-text index only
Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses.
PMID 18477650 · PMC2443277 · Carcinogenesis · 2008 · 8 claims · 7 setups
HBx C-terminal deletion mutants (HBx3'-30 and HBx3'-40) produce differentially expressed gene and protein profiles in transfected Huh7 HCC cells, mostly involving transcriptional regulation, oncogenes/tumor suppressors, cell junctions, signal transduction, metabolism and immune response
-
Full-text index only
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
PMID 41534092 · PMC13044530 · Cancer research · 2026 · 8 claims · 8 setups
SWI/SNF-targeting PROTAC treatment reduces viability of CRPC-WNT (AR-negative) cell lines and organoids, not just AR-dependent CRPC